Cognitive Training to Enhance Depression Relief: Testing an Adjunct to Clinical Esketamine Treatment
试验速览
- 阶段
- 不适用
- 状态
- 暂停
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Quick Inventory of Depressive Symptoms
研究概览
简要总结
In a sample of patients already receiving esketamine treatment as part of their clinical care, this project seeks to test whether we can improve depression by introducing helpful information delivered by a computer-based training protocol. This work could ultimately lead to the ability to treat depression more efficiently and with broader dissemination by rapidly priming the brain for helpful forms of learning.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any patient aged 18-80 in the esketamine clinic in the Center for Interventional Psychiatry. The clinic's extensive screening and eligibility criteria for esketamine treatment will not be altered in any way, other than imposing the study-specific age range and the two
排除标准
- •Exclusion Criteria:
- •Patients who do not expect to remain located in the Pittsburgh area for a minimum of 1 month beyond study enrollment.
- •Patients who, in the judgment of the esketamine clinical medical director, show signs of intellectual disability, developmental disability, and/or cognitive impairment (including age-related cognitive decline) of a sufficient degree to interfere with engagement in any study procedure.
研究组 & 干预措施
Cognitive Training
8 sessions of web-based cognitive training
干预措施: Cognitive Training (Behavioral)
Sham Training
8 sessions of web-based sham training
干预措施: Sham Training (Behavioral)
结局指标
主要结局
Quick Inventory of Depressive Symptoms
时间窗: Trajectories from baseline through 1 month
Self-reported depression (range: 0-27; higher scores = worse outcome)
Montgomery Asberg Depression Rating Scale
时间窗: Trajectories from baseline through 1 month
depression severity; range 0-60; high score=worse outcome
次要结局
- Frequency of scheduled esketamine visits(During first month)
- Clinical Global Impression Scale--Severity(Trajectories from baseline through 1 month)
- Clinical Global Impression Scale--Improvement(Trajectories from baseline through 1 month)
- Number of patients terminated from esketamine therapy(During first 6 months)
- Hamilton Depression Rating Scale modified score(Trajectories from baseline through 1 month)
研究者
Rebecca Price
Associate Professor of Psychiatry and Psychology
University of Pittsburgh